RAPT, US75382E2081

RAPT stock ends as GSK completes USD 2.3 billion deal

Published on 10/04/2026 at 13:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

RAPT stock was fixed at USD 58.00 per share when GSK completed its acquisition on March 3, 2026. Ozureprubart moved into GSK's phase IIb pipeline.

RAPT, US75382E2081, Illustration mit AI erstellt.

RAPT Therapeutics stock (ISIN US75382E2081) was quoted at USD 58.01 on Nasdaq on March 6, 2026 at 10:30 a.m. ET, just USD 0.01 above the USD 58.00 cash consideration set for shareholders. StockTitan reports that GSK completed the acquisition on March 3, 2026.

USD 58.00 fixes the outcome

GSK paid USD 58.00 per share at closing, according to the company's September 2026 Form 6-K carried by StockTitan. The filing puts the aggregate payment at USD 2.3 billion including transaction fees, while the net investment after acquired cash was USD 1.9 billion.

The transaction covered 100 percent of RAPT's outstanding equity. For shareholders, that changes the central reference point from daily price discovery to the contractual cash payment.

Ozureprubart moves into GSK

RAPT developed therapies for inflammatory and immunologic diseases, with ozureprubart as its key food-allergy asset. The GSK filing describes the long-acting anti-IgE antibody as being in phase IIb development for prophylactic protection against food allergens.

The asset transfer gives GSK global rights to the program except mainland China, Macau, Taiwan and Hong Kong, according to StockTitan. That pipeline ownership, rather than a new RAPT earnings report, is now the relevant operating fact for the former listed company.

Last quote reached USD 58.01

RAPT stock was last shown at USD 58.01 on Nasdaq on March 6, 2026 at 10:30 a.m. ET. The same snapshot showed a USD 5.67 to USD 58.02 52-week range, USD 1.6 billion in market capitalization and volume of 10,846,697 shares.